One drug comes out top in a large analysis, external of how effective antidepressants are at keeping patients free of symptoms of depression. Escitalopram performed best at preventing patients from relapsing in a study involving nearly 10,000 people prescribed different medications for up to a year. Two other pills - agomelatine and duloxetine - came next, while prozac (also known as fluoxetine) ranked just below them. Experts stress the findings don't mean that everyone with severe depression should switch to escitalopram, or that other antidepressants aren't any good, because all the drugs can work and each has its pros and cons. Depression is common, affecting around one in six people in the UK. With the right treatment and support, people can make a good recovery although for some their depression can return.

The apps and platforms that help family caregivers manage their loved ones' needs are becoming more capable, but the broader issue of caregivers' well-being remains unsolved. My husband and I are caregivers for our middle son, who has multiple disabilities and requires full-time support. We do our best to keep one another up to date on the activities that fill his daily life while also managing his numerous medical specialists, procedures, and therapies. We have to stay in constant communication while also working our jobs, caring for three teenagers, and managing a household. According to AARP, in 2025, an estimated 63 million Americans cared for adults or children with a medical condition or disability. On average, these caregivers spend up to 27 hours per week providing care.

Gift Ideas For Everyone On Your List Mashable's Best: E-readers, robovacs, laptops, earbuds, smart home and more Look Up Mashable @Home In My Bag Safety Net Versus Trending Now Say More Creator Playbook Mashable Selects Getting Technical with Mashable All Series The lawsuit says the chatbot helped her hide the plan from her doctors in the weeks before she died. Chance Townsend is the General Assignments Editor at Mashable, covering tech, video games, dating apps, digital culture, and whatever else comes his way. He has a Master's in Journalism from the University of North Texas and is a proud orange cat father. His writing has also appeared in PC Mag and . The parents of a 31-year-old Seattle woman are suing OpenAI, alleging the company's AI chatbot led to her death, according to a new report from .

The company plans to offer testosterone replacement therapy, marking its first foray into prescribing controlled substances. Talk of testosterone deficiency is hard to escape these days, with podcasters and politicians obsessing over how to avoid a "low T" lifestyle. As the hormone's cultural salience deepens, demand is growing. In a timely move, telehealth giant Hims just launched a testosterone replacement therapy service for cisgender men. The direct-to-consumer juggernaut will offer two types of injectable treatments, as well as an oral pill option that can be sent to patients after they take an at-home capillary blood test.

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

Say More Versus Trending Now Look Up In My Bag Mashable's Best: E-readers, robovacs, laptops, earbuds, smart home and more Mashable @Home Mashable Selects Top creators, ranked Gift Ideas For Everyone On Your List Creator Playbook AI at School All Series Influencers are shilling libido products. Which ones should you use? Experts break down what's worth your time and money. Anna Iovine is the associate editor of features at Mashable. Previously, as the sex and relationships reporter, she covered topics ranging from dating apps to pelvic pain. Before Mashable, Anna was a social editor at VICE and freelanced for publications such as Slate and the Columbia Journalism Review.

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

Journalist hilariously fails claiming WNBA's popularity isn't affected by Caitlin Clark's playoff exit Cooper Gallant slept in his truck for years chasing pro fishing dream: 'I didn't have a Plan B' Deion Sanders dared the media to write the truth about Colorado football: Ok, it's time to end this charade Madison Beer is being accused of ruining Justin Herbert's career, sad Eagles fans & Yankees fans fighting Bears' Devin Bush says win over Jets was'probably one of the easiest NFL games I have played in' WWE great Diamond Dallas Page'would love to see' LA Knight capture title vs Roman Reigns at Money in the Bank Jack Smith wears'No Kings' shirt just days after Trump hearing This man was radicalized by the Taliban. Art Laffer on socialism threat: 'I don't think these guys are serious' Ken Griffin's $3 BILLION donation sparks NYC vs Miami debate We've seen this playbook before, Gen. Keane says The all-time goal-scoring leader with 929 goals shared his decision ahead of the Capitals' home opener against Pittsburgh Well, it's great that he apologized. Who exactly is he apologizing to? Alex Ovechkin announced on Monday ahead of the Washington Capitals home opener against the Pittsburgh Penguins that this season will be his last in the National Hockey League. The 41-year-old signed a one-year contract during the offseason to return to Washington for what is his 22nd season in the NHL, all of which he has spent in the nation's capital.

The device made by Flow Neuroscience is approved by the FDA and could help people get off antidepressants--but it costs $2,200. An at-home wearable for the treatment of depression is now available by prescription in the US. With roughly one in six American adults taking an antidepressant medication, Swedish firm Flow Neuroscience is positioning its device as an alternative to traditional drugs. But at the current four-figure price tag, it might take a while for the futuristic-looking headset to catch on with patients. Worn on the forehead for 30 minutes a day and operated with an app, the device provides low-intensity electrical stimulation to the left frontal lobe of the brain, an area involved in regulating mood and emotions.

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?